Literature DB >> 27207095

Feasibility and Outcomes of the Third or More Episodes of Sequential Microvascular Reconstruction for Recurrent or Second Primary Oral Cancer.

Anaeze C Offodile1, Kai-Ping Chang2, Hsin-Hung Chen3, Eric Loesch4, Shao-Yu Hung3, Huang-Kai Kao5.   

Abstract

BACKGROUND: This study was a robust examination of the clinical outcomes and technical feasibility of sequential microvascular reconstruction for recurrent or second primary oral cancer.
METHODS: A retrospective, cross-sectional analysis of adult patients undergoing microvascular reconstruction of head and neck oncologic defects was performed at Chang Gung Memorial Hospital, spanning 10 years. The patients were divided into three groups as follows: first episode, second episode, and third or more episodes of reconstruction. Demographics, operative details, and clinical outcomes were compared.
RESULTS: The study cohort included 3186, 319, and 62 patients who respectively received first, second, and third or more episodes of reconstruction. The most common tumor sites were the tongue (36.9 %) and the buccal region (36.8 %), with squamous cell carcinoma as the prevalent histology. The anterior lateral thigh was the most popular donor site used (76.1 %). The third or more episodes of microvascular reconstruction were associated with an increased incidence of flap failure (8.1 %) relative to the first (1.9 %; p = 0.003) and the second (1.6 %; p = 0.01) episodes. Re-exploration of venous occlusion (9.7 vs. 3.2 %), neck wound infections (53.2 vs. 35.5 %), fistula (17.7 vs. 8.1 %), and hospital stay (28.9 ± 14.6 vs. 25.3 ± 10.1) also showed significantly higher values for the third or more episodes group than for the first episode group.
CONCLUSIONS: Sequential microvascular reconstruction for recurrent or second primary oral cancer is associated with an increased incidence of postoperative complications. However, in appropriate candidates for repeat ablation, microvascular reconstruction remains the gold standard for attaining functional and cosmetic outcomes.

Entities:  

Mesh:

Year:  2016        PMID: 27207095     DOI: 10.1245/s10434-016-5283-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Assessing the suitability of medial sural artery perforator flaps in tongue reconstruction - An outcome study.

Authors:  Shao-Yu Hung; Charles Yuen Yung Loh; Soo-Ha Kwon; Chia-Hsuan Tsai; Kai-Ping Chang; Huang-Kai Kao
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

2.  Third Repeat Microvascular Reconstruction in Head and Neck Cancer Patients Aged 65 Years and Older: A Longitudinal and Sequential Analysis.

Authors:  Jonas Löfstrand; Kai-Ping Chang; Jennifer An-Jou Lin; Charles Yuen Yung Loh; Hsuan-Yu Chou; Huang-Kai Kao
Journal:  Sci Rep       Date:  2017-11-16       Impact factor: 4.379

3.  Sequential reconstruction for recurrent head and neck cancer: A 10-year experience.

Authors:  Soon Won Chung; Il Hwan Byun; Won Jai Lee
Journal:  Arch Plast Surg       Date:  2019-09-15

Review 4.  Do medial sural artery perforator flaps have better clinical outcomes compared to the rectus abdominis perforator (DIEAP) flap in reconstruction of glossectomy defects? A Prisma guided meta-analysis.

Authors:  Rathindra Nath Bera; Preeti Tiwari
Journal:  Ann Maxillofac Surg       Date:  2021-07-24

Review 5.  Salvage Surgery in Recurrent Oral Squamous Cell Carcinoma.

Authors:  K S Rathan Shetty; Vinayak Kurle; P Greeshma; Veena B Ganga; Samskruthi P Murthy; Siddappa K Thammaiah; P Krishna Prasad; Purushottham Chavan; Rajshekar Halkud; R Krishnappa
Journal:  Front Oral Health       Date:  2022-01-28

6.  Remote ischemic preconditioning does not influence lectin pathway protein levels in head and neck cancer patients undergoing surgery.

Authors:  Kristine Frederiksen; Andreas Engel Krag; Julie Brogaard Larsen; Birgitte Jul Kiil; Steffen Thiel; Anne-Mette Hvas
Journal:  PLoS One       Date:  2020-04-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.